Not So Different: Charles Bennett, MD, PhD, Discusses Why the FTC Needs to Join the Effort to Improve the Biosimilar Market

January 10, 2021


We spoke to Charles Bennett, MD, PhD, a clinical pharmacy specialist, about his recent oncology biosimilars study and how pay-for-delay schemes have somewhat stalled the biosimilar market.

The Leading “Not So Different” Podcast Episodes of 2020

December 30, 2020


Here are some of our most-listened-to 2020 "Not So Different" podcasts.

Sean McGowan on What’s in Store for Biosimilars in 2021 and Beyond

December 6, 2020


Sean McGowan, senior director of Biosimilars at AmerisourceBergen, discusses how 2020 has affected biosimilar development and his predictions for the industry going forward.

Not So Different: A Trio of Experts on What Needs to Change to Boost Biosimilar Adoption

November 29, 2020


We sat down with a trio of experts to discuss the factors currently impacting biosimilar adoption, what reforms are needed to improve it, and what stakeholders can do to help.

Not So Different: Kathy Oubre on the Benefits of Using Biosimilars in a Community Oncology Practice

November 15, 2020


Kathy Oubre, MS, chief operating officer at the Pontchartrain Cancer Center in Louisiana, discusses the value of biosimilars.

Not So Different: Steven C. Hill, PhD, Discusses Rebates and Specialty Drug Spending

November 8, 2020


In an interview with The Center for Biosimilars®, Steven C. Hill, PhD, a senior economist with the Agency for Healthcare Research and Quality, discusses a recent study he co-authored on specialty drug spending.

Not So Different: Nancy Globus, PharmD, on Whether Comparative Efficacy Trials are Necessary

October 25, 2020


We spoke with Nancy J. Globus, PharmD, vice president of Regulatory Affairs at the Accreditation Council for Medical Affairs, for her take on requirements for comparative efficacy trails and whether they add meaningful data for the purposes of biosimilar acceptance.

Not So Different: Kathy Oubre on What Oncology Practices Have Lacked During the Pandemic

October 18, 2020


We sat down with Kathy Oubre, chief operating officer at the Pontchartrain Cancer Center, to discuss what practices have had to forgo during the coronavirus disease 2019 (COVID-19) crisis and how biosimilar access has been affected.

Not So Different: Kanika Monga, MD, and Angus Worthing, MD, Discuss ACR Survey on Biosimilars and COVID-19

October 11, 2020


Kanika Monga, MD, of the American College of Rheumatology’s (ACR) Communication and Marketing Committee, and Angus Worthing, MD, an ACR director, discuss the ACR's recent survey on rheumatology.

Wayne Winegarden, PhD, on Downside of Importing Drugs From Canada

October 4, 2020


We sat down with Wayne Winegarden, PhD, a senior fellow in business and economics at the Pacific Research Institute (PRI) and director of PRI's Center for Medical Economics and Innovation, to discuss why the FDA’s implementation of the Safe Importation Action Plan is controversial.